From disease elimination to elimination of the oncogenic HPVs
University of Tampere, University of Helsinki, Karolinska Institutet
Kurssinumero: 108
Puheenjohtaja:
Yhdyshenkilö: prof. Matti Lehtinen, University of Tampere, Karolinska Institutet
prof. Jorma Paavonen, HUS
Tavoite: kansainvälisen HPV-rokotetutkimuksen tulosten esittely, ja HPV-rokoteohjelman vaikuttavuuden arviointi HPV-tautien ja/tai taudin-aiheuttajan eliminoimiseksi
Kohderyhmä: kaikki asiasta kiinnostuneet lääkärit
Erikoistuminen: hyväksytty 6 tuntia, alat naistentaudit ja synnytykset, kliininen mikrobiologia, infektiosairaudet, patologia
Erityispätevyys:
Paikka: 209
Aika: 13.1.2016 08:00 - 16:20
Kurssimateriaalia ladattavissa Fimnet-tunnistautumisen jälkeen.
08:00 Opening
Dr. Hannu Halila, Finnish Medical AssociationDr. Pauli Leinikki Elimination of HPV-associated cancers
prof. Jorma Paavonen, The Hospital District of Helsinki and Uusimaa08:15 HPV self-sampling is here
Dr. Peter Snijders, Free University of Amsterdam08:40 Screening of HPV vaccinated women
Dr. Pekka Nieminen, The Hospital District of Helsinki and Uusimaa09:05 Elimination of cervical cancer from Europe
Dr. Xavier Bosch, Catalan Institute of Oncology09:30 Elimination of cervical cancer from developing countries
Dr. Silvia Franceschi, International Agency for Research on Cancer09:55 Cost-effectiveness of elimination of HPV-associated cancers
Dr. Mark Jit, Public Health England10:20 Coffee break
Understanding biology of prophylactic HPV-vaccinationtion
Dr. Margaret Stanley, Cambridge University10:50 Infection and vaccine induced HPV immune responses
Dr. Margaret Stanley, Cambridge University11:15 How do HPV vaccines protect?
Dr. Joakim Dillner, Karolinska Institutet11:40 Cross-neutralizing, HPV-vaccine induced ab-response
Dr. Mahboobeh Safaeian, National Cancer Institute12:05 Duration of HPV-vaccine induced antibody response
Dr. Michael Pawlita, Deutsches Krebsforschungszentrum12:30 Lunch
Elimination of major oncogenic HPV types
Dr. Geoff Garnett, Gates Foundation13:30 Herd effect generated by gender-neutral HPV vaccination
Prof. Matti Lehtinen, University of Tampere, Karolinska Institutet13:55 Vaccine induced cross-protection - type-replacement
Dr. Eduardo Franco, McGill University, Montreal14:20 Systematic review of studies on type-replacement
Dr. David Mesher, Public Health England14:45 Coffee break
15:10 Elimination of HPV from different countries
Dr. Iacopo Baussano, International Agency for Research on Cancer15:35 Impact of HPV elimination
Dos. Simopekka Vänskä, Institute for Health &Welfare16:00 Conclusion
Dr. Geoff Garnett, Gates Foundation